glp 1 agonist vision loss Glucagon-like peptide-1 receptor: mechanisms and advances in therapy Doctors are tracking rare reports

OZEMPIC: Risks, Benefits, and Natural Alternatives to GLP-1 Weight-Loss Drugs Michael Greger, M.D

Phase 2 clinical trial data published in the New England Journal of Medicine (Jastreboff et al., 2023) demonstrated mean body weight reductions of up to approximately 24% over 48 weeks in adults with obesity a notable finding, though long-term durability data and head-to-head comparisons with other treatments are not yet available

Gastroenterology & Hepatology 12 (4), 231242

Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial

I think it helps me to feel like the best version of myself

The result is a holistic boost to your well-being